The Scripps Translational Science Institute (STSI) has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to advance medical research and clinical care through genomic and digital technologies.

According to STSI, this is the third 5-year Clinical and Translational Science Award (CTSA) it has received since 2008, and it will be used to provide resources and infrastructure support for STSI to further its mission of applying genomic and digital technologies, coupled with bioinformatics tools to better understand each individual and ultimately render more effective care.

Eric Topol, MD, Principal Investigator for the CTSA, Director of STSI and Executive VP at TSRI.

“We are thrilled to have the NIH’s continued support for our efforts to advance individualized medicine, both in care of patients and in training of young physicians and scientists,” says Dr. Eric Topol. 

As part of the CTSA, STSI has formed a new partnership with Rady Children’s Institute for Genomic Medicine, a leader in ultra-rapid, whole-genome sequencing programs in acutely ill infants.

“Genomic medicine research programs at STSI and Rady Children’s synergise significantly, especially as related to the genetics of rare and infectious diseases,” Rady’s CEO, Dr. Stephen Kingsmore, said in a statement. “We are looking forward to working closely with Dr. Topol’s team to advance the implementation of genomic medicine in our region of southern California and through the national CTSA consortium.”

Kingsmore Has Done it Again: Rady Children’s Set Guinness World Record for Genetic Diagnosis

In addition, the CTSA renewal features a drug discovery collaboration between STSI and another of TSRI’s affiliated institutes, the California Institute for Biomedical Research (Calibr), which focuses on the translation of basic research to new medicines that address unmet medical needs.

“We are thrilled to enable the broader Scripps Research mission by partnering with STSI to engage the CTSA network, bringing to bear drug discovery tools that could enable rapid translation of new therapeutic approaches to patients,” Calibr Chief Operating Officer Matt Tremblay added.